Octapharma Ag

Octagene Gmbh

Carola Schröder

Elisabeth Casademunt

Michael Lehnerer

Helena Sandberg

Maya Tiemeyer

Peter Stenlund

Peter Söhlemann

Charlotte Hauser

Andrea Hörster

A recombinant human factor VIII or IX protein having a human glycosylation pattern but the protein is devoid of N-glycolylneuraminic acid and/or the carbohydrate group Gal&#x3b1;-3Gal.

Recombinantly produced human factor VIII and IX

A G-CSF precursor comprising a signal peptide and a G-CSF peptide, wherein the signal peptide has the sequence of the human wild-type signal peptide of the human G-CSF/b molecule with at least one of the following mutations:

Processing of recombinant human G-CSF precursor

The present invention relates to an improved method for the production of recombinant human blood clotting factors, in particular of factor VIII and factor IX. An immortalized human cell line can be used to stably express viral transcription activator proteins and carrying a vector having a promoter functionally linked to a DNA sequence coding for a blood coagulating factor, provided that said promoter is not a viral promoter which is stimulated by said viral transcription activator proteins. The invention further relates to an immortalized human cell line carrying said vector, factor VIII muteins particularly suitable for the above production method; pharmaceutical compositions comprising such factor VIII muteins, and the use of such factor VIII muteins for preparing a medicament for treating hemophilia.

Recombinant blood clotting factors

Growing community of inventors

Neuried, Germany

Carola Schröder